The immense challenges posed by the coronavirus pandemic are fueling interest in cloud computing among vaccine researchers, clinicians, healthcare companies and patients across Asia.
With the Covid-19 pandemic increasingly forcing healthcare testing, diagnosis and treatment online, the promise of augmented and virtual reality is drawing deepening interest in Asia’s medtech market.
The Chinese government is investing heavily in the development of new technologies that leverage AI. This includes solutions to address the COVID-19 outbreak.
Across the continent, governments and hospitals are purchasing robotics systems from abroad as well as developing the technologies themselves.
It is the pot of gold at the end of the medical rainbow—the promise that, by harnessing data, researchers can tailor drugs, devices, and treatments to the genetic configuration, lifestyle, and environment of individual patients.
This major health threat is driving demand for more diagnostic tests and devices to treat cardiac problems.
This mode of personalized medicine helps doctors make more informed decisions related to drug therapies.
Digital reality technologies are fast emerging as promising tools to aid physicians and patients. Western and Asian medtech companies are becoming big players in the growing market for these new applications in Asia.
The race to apply AI to medical treatment is rapidly accelerating in China and Japan.
Breast cancer is on the rise across Asia, with more women contracting the disease than ever before.